The update of the ESTC was conducted as a joint endeavour with ERS, consulting experts from international societies and organisations, national TB programmes, civil society and affected communities. The second edition of the ESTC includes 21 standards in the areas of diagnosis, treatment, HIV and co...-morbidities and public health and prevention. The ESTC is a user-friendly guide for clinicians and public health workers to help them achieve optimal diagnosis, treatment and prevention of TB
Available in 25 languages: https://ecdc.europa.eu/en/all-topics-ztuberculosisprevention-and-control/european-union-standards-tuberculosis-care
more
These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenc...ed below.
This document has been updated: Version 15 March 2022.
more
nterim guidance, first issued 25 January 2021, updated 15 June 2021, updated 19 November 2021, updated 23 February 2022, updated 18 August 2022
first issued 18 August 2022
Although Kenyans enjoy comparatively good health, the prevalence of
chronic disease is increasing and our ageing population is placing evergrowing pressures on the finite resources of our health system.
This document focuses on making recommendations for the diagnosis and treatment of Chagas disease, an infection caused by Trypanosoma cruzi, the protozoan agent of a systemic parasitic disease. Methodology: These clinical practice guidelines were prepared following the WHO handbook for guideline dev...elopment (5). A multidisciplinary development group was formed, comprised of thematic experts, epidemiologists, methodologists, and users. Since there were no existing guidelines that could be adapted, the guidelines were developed from scratch.
more
ECDC Technical Report
In line with ECDC’s recommendations provided in the ’Risk Assessment of HTLV-1/2 transmission by tissue/cell transplantation’ dated 14 March 2012, this Directive replaces the term ‘incidence’ with ‘prevalence’ in the description of endemic areas of HTLV-1/2 i...nfection. According to the new requirements ‘HTLV-1 antibody testing must be performed for donors living in, or originating from high-prevalence areas or with sexual partners originating from those areas or where the donor’s parents originate from those areas’ and this applies to both donors of non-reproductive tissues and cells and reproductive cells.
ECDC contracted experts from the Institut Pasteur in Paris to systematically review the published evidence on the distribution of HTLV-1 infection prevalence throughout the world and to identify high-prevalence countries and areas.
more
orientations provisoires, première publication le 25 janvier 2021, mise à jour le 15 juin 2021, mise à jour le 19 novembre 2021
Chapter 2 in "Latest Findings in Intellectual and Developmental Disabilities Research" Edited by Üner Tan, ISBN 978-953-307-865-6, 404 pages, Publisher: InTech, Chapters published February 15, 2012 under CC BY 3.0 license | Intellectual and Developmental Disabilities presents reports on a wide rang...e of areas in the field of neurological and intellectual disability, including habitual human quadrupedal locomotion with associated cognitive disabilities, Fragile X syndrome, autism spectrum disorders, Down syndrome, and intellectual developmental disability among children in an African setting. Studies are presented from researchers around the world, looking at aspects as wide-ranging as the genetics behind the conditions to new and innovative therapeutic approaches. (All chapters available online: https://www.intechopen.com/books/latest-findings-in-intellectual-and-developmental-disabilities-research)
more
Chromoblastomycosis (CBM), represents one of the primary implantation mycoses caused by melanized fungi widely found in nature. It is characterized as a Neglected Tropical Disease (NTD) and mainly affects populations living in poverty with significant morbidity, including stigma and discrimination.
Organización Mundial de la Salud. (2022). Recomendaciones provisionales sobre el uso de la vacuna CanSinoBIO Ad5-nCoV-S [recombinante] (Convidecia™) contra la COVID-19: orientaciones provisionales, primera publicación: 19 de mayo de 2022.
Manual para directores de programas
Rev Saude Publica. 2022; 56: 22.
Published online 2022 Apr 11. doi: 10.11606/s1518-8787.2022056004040
We are IntechOpen, the world’s leading publisher of Open Access books Built by scientists, for scientists
Selection of our books indexed in the Book Citation Index in Web of ScienceTM Core Collection (BKCI)
http://dx.doi.org/10.5772/intechopen.68759
orientaciones provisionales, primera publicación: 24 de mayo de 2021, actualización: 21 de octubre de 2021, actualización: 15 de marzo de 2022
Print version ISSN 1809-9823On-line version ISSN 1981-2256
Rev. bras. geriatr. gerontol. vol.19 no.2 Rio de Janeiro Mar./Apr. 2016
http://dx.doi.org/10.1590/1809-98232016019.150040
These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
fir...st issued 8 January 2021, updated 15 June 2021, updated 19 November 2021, updated 21 January 2022, updated 18 August 2022. Available in other languages https://apps.who.int/iris/handle/10665/361720
more
A manual for programme managers.
БОРЬБА С ТУБЕРКУЛЕЗОМ В ТЮРЬМАХ
Руководство для руководителей программ